Akebia Therapeutics, Inc. (AKBA)
NASDAQ: AKBA · Real-Time Price · USD
1.710
+0.080 (4.91%)
At close: Oct 29, 2024, 4:00 PM
1.700
-0.010 (-0.58%)
After-hours: Oct 29, 2024, 7:56 PM EDT
Akebia Therapeutics Employees
Akebia Therapeutics had 167 employees as of December 31, 2023. The number of employees decreased by 38 or -18.54% compared to the previous year.
Employees
167
Change (1Y)
-38
Growth (1Y)
-18.54%
Revenue / Employee
$1,044,892
Profits / Employee
-$242,168
Market Cap
359.59M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Enhabit | 10,800 |
DocGo | 4,164 |
Viemed Healthcare | 996 |
Anika Therapeutics | 357 |
Nano-X Imaging | 164 |
ProQR Therapeutics | 157 |
Nyxoah | 147 |
ClearPoint Neuro | 107 |
AKBA News
- 7 days ago - Akebia Therapeutics Signs Commercial Supply Contract with Leading Dialysis Organization to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis - PRNewsWire
- 14 days ago - Akebia Therapeutics Announces Seven Poster Presentations at ASN Kidney Week 2024 - PRNewsWire
- 19 days ago - CMS Grants TDAPA Reimbursement for Vafseo® (vadadustat) beginning January 1, 2025 - PRNewsWire
- 22 days ago - Akebia Therapeutics and U.S. Renal Care Sign Commercial Supply Contract to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis - PRNewsWire
- 4 weeks ago - Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 7 weeks ago - Akebia Therapeutics and U.S. Renal Care Initiate the VOICE Trial of Vafseo® (vadadustat) for Patients on Dialysis - PRNewsWire
- 2 months ago - Akebia Therapeutics to Present at Upcoming Investor Conferences - PRNewsWire
- 2 months ago - Akebia Therapeutics, Inc. (AKBA) Q2 2024 Earnings Call Transcript - Seeking Alpha